Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sun Pharma Advanced Research Co Ltd Receives US FDA Response On Levetiracetam NDA

Saturday, 4 May 2013 08:59am EDT 

Sun Pharma Advanced Research Co Ltd announced the receipt of a complete response letter from U.S. Food and Drug Administration on New Drug Application for Levetiracetam Extended release tablets, 1000 mg and 1500 mg, an anti-epileptic product. In the complete response letter, the FDA specified that the clinical data submitted by SPARC establishes, bioequivalence in the fasted state. 

Company Quote

-1.35 -0.74%
25 Jul 2014